Skip to main content

Exousia Bio

Scientific & clinical leadership

Nine Decades of Neuroscience & Therapeutic Innovation

Kiminobu Sugaya, Ph.D.

Founder & Chief Scientific Officer

Background

40+ years in neuroscience, stem cell biology, gene therapy, cancer research, and extracellular vesicle/exosome technology.

Academic

Professor of Medicine and Head of the Neuroscience Division at the Burnett School of Biomedical Sciences, University of Central Florida College of Medicine. Chair of the UCF Institutional Review Board.

Track record

Author of more than 250 scientific publications with over 5,700 citations, and inventor on more than 30 issued patents spanning stem cell biology, neurological therapeutics, cancer, gene delivery, extracellular vesicle technologies, and computer science.

Recognition

Fellow of the National Academy of Inventors (2016), Honorary Professor, and recipient of international honors recognizing contributions to stem cell research and regenerative medicine.

Marvin S. Hausman, M.D.

Chief Medical Officer & Director

Background

Board-certified urological surgeon and immunologist with over 50 years of pharmaceutical drug research and development experience, including tenure with Bristol-Myers International, Mead-Johnson, E.R. Squibb, and Medco Research.

Track record

Domestic and international executive experience in strategic alliances, partnership development, negotiations, acquisitions of breakthrough medical technology, and the launch of numerous public and private biotechnology corporations. Served as CEO or President of several publicly traded medical technology companies, including Axonyx, Inc. and Ludwig Enterprises.

At Exousia

Provides strategic and clinical-development leadership supporting the advancement of Exousia Bio’s oncology programs, including regulatory strategy, orphan-drug development, and commercialization planning.